Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment

Direct-acting antivirals (DAAs) have revolutionised the treatment of Hepatitis C virus (HCV), allowing the World Health Organisation (WHO) to set a target of eliminating HCV by 2030. In this study we aimed to investigate glecaprevir and pibrentasvir (GP) treatment outcomes in a cohort of patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Rajiv, Barclay, Stephen T., Peters, Erica S., Fox, Ray, Gunson, Rory, Bradley-Stewart, Amanda, Shepherd, Samantha J., MacLean, Alasdair, Tong, Lily, van Vliet, Vera Jannie Elisabeth, Ngan Chiu Bong, Michael, Filipe, Ana, Thomson, Emma C., Davis, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416734/
https://www.ncbi.nlm.nih.gov/pubmed/36016300
http://dx.doi.org/10.3390/v14081678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416734/
https://www.ncbi.nlm.nih.gov/pubmed/36016300
http://dx.doi.org/10.3390/v14081678

Ejemplares similares